APA (7th ed.) Citation

Kim, S. T., Lee, J., Park, S. H., Park, J. O., Park, Y. S., Kang, W. K., . . . Lim, H. Y. (2017). Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy. BMC Cancer, 17, 1. https://doi.org/10.1186/s12885-017-3196-6

Chicago Style (17th ed.) Citation

Kim, Seung Tae, et al. "Prospective Phase II Trial of Everolimus in PIK3CA Amplification/mutation And/or PTEN Loss Patients with Advanced Solid Tumors Refractory to Standard Therapy." BMC Cancer 17 (2017): 1. https://doi.org/10.1186/s12885-017-3196-6.

MLA (9th ed.) Citation

Kim, Seung Tae, et al. "Prospective Phase II Trial of Everolimus in PIK3CA Amplification/mutation And/or PTEN Loss Patients with Advanced Solid Tumors Refractory to Standard Therapy." BMC Cancer, vol. 17, 2017, p. 1, https://doi.org/10.1186/s12885-017-3196-6.